http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RS-51613-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f9a36328274867f46f8fc1fb9c868703 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D317-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D413-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D205-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07F7-1892 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D205-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D317-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D413-06 |
| filingDate | 2006-12-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e1b2713eb32252907cc3d98c19f6231 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f6de0b4b8caccb3bb3de41b36eb9b433 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3f6ec83acb75458a2eaf605396f5f9a8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f6a26222ffd3ecd08f1b284835cf137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6dd676ae2c4a3da75b6c832bae99fafa http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bf11d0863974cda74406f56567409256 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5af0bff00b2ce0e507581e90dcbac36 |
| publicationDate | 2011-08-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RS-51613-B |
| titleOfInvention | PROCEDURE FOR THE PRODUCTION OF EZETIMIB AND INTERMEDIERS USED IN THIS PROCESS |
| abstract | A process for the production of ezetimibe represented by Formula I, comprising the steps of: a) translating the ethylene glycol 4- (4Tfluorobenzoyl) -butyric acid represented by Formula II into 4- [2- (4-fluoro-phenyl) - [l , 3] dioxolan-2-yl] -butyric acid represented by formula IV via an unprepared transition compound represented by formula III, b) acylation of a chiral compound represented by formula V with a compound represented by formula IV to give the acylated oxazolidinone derivative represented by formula VI, wherein the compound represented by formula V selected from the group of compounds represented by formulas Va, Vb, Vc, or Vdi where R1, R2 and R3 represent: in the case of Va: R1 = Ph, R2 = R3 = H, in the case of Vb: R1 = R2 = R3 = Ph , in the case of Vc: R1 = methyl, R2 = Ph, R3-Hu in the case of Vd: R1 = isopropyl, R2 = R3 = Ph, and where Ph represents a phenyl group.c) reacting an acylated oxazolidinone represented by formula VI with a protected imine represented by formula VII, and isolating the compound n) represented by formula VIII, wherein R4 represents a silyl group, cyclization of the compound represented by formula VIII to obtain the protected azetidinone derivative of general formula IX, d) hydrolysis of the ketal group of the compound represented by formula IX to give the compound represented by formula X, e) enantioselective reduction a compound represented by general formula X to give a compound represented by formula XI, wherein one of the chiral CBS-oxaborolidine compounds represented by formulas XIIa, XIIb, XIIc XIId is selected as a catalyst, if) eliminating a silyl protected group of compounds of general formula XI in order to end product received ezetimibe represented by Formula I, the Application contains 7 more dependent claims. |
| priorityDate | 2005-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.